drug
vasopressin
Marketedupdated 6mo agoby Par Pharmaceutical Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying vasopressin
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 30, 2035
~8.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (49)
- Sep 27, 2044formulationUS 12447190
- Sep 27, 2044formulationUS 12447190
- Jan 30, 2035method-of-use (U-1857)US 10010575
- Jan 30, 2035method-of-use (U-1857)US 10010575
- Jan 30, 2035method-of-use (U-1857)US 10010575
- Jan 30, 2035method-of-use (U-1857)US 10010575
- Jan 30, 2035formulationUS 12186362
- Jan 30, 2035formulationUS 12186362
- Jan 30, 2035formulationUS 12186362
- Jan 30, 2035formulationUS 12186362
- Jan 30, 2035method-of-use (U-1857)US 9375478
- Jan 30, 2035method-of-use (U-1857)US 9375478
- Jan 30, 2035method-of-use (U-1857)US 9687526
- Jan 30, 2035method-of-use (U-1857)US 9687526
- Jan 30, 2035method-of-use (U-1857)US 9744209
- Jan 30, 2035method-of-use (U-1857)US 9744209
- Jan 30, 2035method-of-use (U-1857)US 9744239
- Jan 30, 2035method-of-use (U-1857)US 9744239
- Jan 30, 2035formulationUS 9750785
- Jan 30, 2035formulationUS 9750785
- Jan 30, 2035formulationUS 9919026
- Jan 30, 2035formulationUS 9919026
- Jan 30, 2035formulationUS 9919026
- Jan 30, 2035formulationUS 9919026
- Jan 30, 2035method-of-use (U-1857)US 9925233
- Jan 30, 2035method-of-use (U-1857)US 9925233
- Jan 30, 2035method-of-use (U-1857)US 9925233
- Jan 30, 2035method-of-use (U-1857)US 9925233
- Jan 30, 2035method-of-use (U-1857)US 9925234
- Jan 30, 2035method-of-use (U-1857)US 9925234
- Jan 30, 2035method-of-use (U-1857)US 9925234
- Jan 30, 2035method-of-use (U-1857)US 9925234
- Jan 30, 2035method-of-use (U-1857)US 9937223
- Jan 30, 2035method-of-use (U-1857)US 9962422
- Jan 30, 2035method-of-use (U-1857)US 9962422
- Jan 30, 2035method-of-use (U-1857)US 9962422
- Jan 30, 2035method-of-use (U-1857)US 9962422
- Jan 30, 2035method-of-use (U-1857)US 9968649
- Jan 30, 2035method-of-use (U-1857)US 9968649
- Jan 30, 2035method-of-use (U-1857)US 9968649
- Jan 30, 2035method-of-use (U-1857)US 9968649
- Jan 30, 2035method-of-use (U-1857)US 9974827
- Jan 30, 2035method-of-use (U-1857)US 9974827
- Jan 30, 2035method-of-use (U-1857)US 9974827
- Jan 30, 2035method-of-use (U-1857)US 9974827
- Jan 30, 2035method-of-use (U-1857)US 9981006
- Jan 30, 2035method-of-use (U-1857)US 9981006
- Jan 30, 2035method-of-use (U-1857)US 9981006
- Jan 30, 2035method-of-use (U-1857)US 9981006
News(2)
- Estuary flows out of stealth with $103M to propel kidney disease gene therapies into clinicEstuary Biotherapeutics has swum out of stealth with $103 million in funding to power a pair of gene therapies into clinical trials for an inherited kidney disorder.fiercebiotech · 1mo ago
- White House takes stock of US-based manufacturing for 86 essential drugsThe White House's Office of Management and Budget (OMB) is asking for more information on the domestic production of 86 essential medicines, such as the pain reliever aspirin and the blood pressure…endpoints · 1mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that